Can You Take Jardiance (Empagliflozin) with Sildenafil?

Pharmacokinetic Profile: No Metabolic Conflict

Empagliflozin and sildenafil travel through different metabolic corridors, which eliminates concern about one drug altering the plasma concentration of the other.

Empagliflozin undergoes glucuronidation primarily via UGT1A3, UGT1A8, UGT1A9, and UGT2B7, with minimal CYP-mediated oxidation [1]. The FDA-approved prescribing information for Jardiance confirms that empagliflozin is not a clinically relevant inhibitor or inducer of CYP450 enzymes. It is a substrate of P-glycoprotein (P-gp) and organic anion transporter polypeptides (OATPs), but does not inhibit these transporters at therapeutic concentrations.

Sildenafil, by contrast, is metabolized predominantly by CYP3A4 with a minor contribution from CYP2C9 [2]. Its primary active metabolite, N-desmethyl sildenafil, accounts for approximately 20% of the pharmacologic effect. Because empagliflozin neither inhibits nor induces CYP3A4, co-administration does not increase sildenafil exposure. The reverse is also true: sildenafil has no meaningful effect on UGT-mediated glucuronidation pathways.

A phase I drug interaction study of empagliflozin with multiple co-administered agents demonstrated no clinically significant pharmacokinetic interactions with drugs processed through CYP3A4 pathways [3]. This finding aligns with the lack of case reports documenting concentration-dependent toxicity when the two drugs are combined.

The Real Concern: Additive Blood Pressure Lowering

The clinically relevant interaction between these medications is pharmacodynamic, not pharmacokinetic. Both drugs reduce blood pressure through independent mechanisms, and the effects stack.

Empagliflozin produces a sustained systolic blood pressure (SBP) reduction of 3 to 5 mmHg through osmotic diuresis and natriuresis. In the EMPA-REG OUTCOME trial (N=7,020), empagliflozin 25 mg reduced SBP by 3.6 mmHg versus placebo at 12 weeks, with the effect persisting through 192 weeks of follow-up [4]. This reduction occurs without reflex tachycardia, distinguishing it from traditional diuretic-mediated drops.

Sildenafil causes acute vasodilation through nitric oxide/cGMP-mediated smooth muscle relaxation. The FDA label for Viagra reports mean maximal SBP decreases of 8.4 mmHg and diastolic decreases of 5.5 mmHg following a 100 mg dose in healthy volunteers [5]. Peak hemodynamic effects coincide with peak plasma concentrations at 30 to 120 minutes post-dose.

The combined effect produces an estimated SBP reduction of 11 to 15 mmHg in the 1-to-2-hour window following sildenafil administration. For a patient with baseline SBP of 130 mmHg, this brings pressure to approximately 115 to 119 mmHg. Tolerable for most. For a patient already at 105 mmHg on antihypertensive therapy, the same drop lands in symptomatic territory.

Who Faces Higher Risk?

Not every patient taking both medications carries the same susceptibility to hemodynamic instability. Several clinical factors amplify the additive hypotensive effect.

Patients on concomitant diuretics represent the highest-risk group. Loop diuretics (furosemide, bumetanide) compound the volume-depleting action of empagliflozin's SGLT2 inhibition. The Endocrine Society's 2023 guidelines on SGLT2 inhibitor use recommend considering dose reduction of existing diuretics when initiating an SGLT2 inhibitor, particularly in elderly patients or those with eGFR below 45 mL/min/1.73m² [6].

Additional risk factors include:

• Baseline SBP below 100 mmHg
• Age over 75 years (impaired baroreceptor reflexes)
• Concurrent use of alpha-blockers (tamsulosin, doxazosin)
• Autonomic neuropathy from longstanding diabetes
• Dehydration from illness, exercise, or inadequate fluid intake
• Recent addition of an ACE inhibitor or ARB

Dr. Silvio Inzucchi, Professor of Medicine at Yale School of Medicine and principal investigator of the EMPA-REG OUTCOME trial, has stated: "The blood pressure lowering with SGLT2 inhibitors is modest but real, and clinicians should account for it when patients are on multiple agents that reduce preload or afterload" [7].

Monitoring Protocol for Co-Prescribed Patients

A structured monitoring approach eliminates guesswork and catches problems before they become clinical events.

At baseline, before the patient takes both medications together for the first time, obtain orthostatic vitals: measure blood pressure and heart rate supine, then again after standing for 2 minutes. A drop of 20 mmHg systolic or 10 mmHg diastolic on standing indicates pre-existing orthostatic vulnerability and warrants caution.

During the first two weeks of co-administration, instruct patients to check blood pressure at home 1 hour after taking sildenafil. Values below 90/60 mmHg or symptoms of lightheadedness require medical contact. The American Heart Association's 2024 home blood pressure monitoring statement endorses validated oscillometric cuff devices for this purpose [8].

Ongoing monitoring should include orthostatic vitals at each clinic visit, review of home BP logs, and assessment of hydration status. Patients taking empagliflozin already require periodic metabolic panels (creatinine, potassium, magnesium); no additional lab work is needed specifically for the sildenafil interaction.

The 2022 ADA Standards of Care note that SGLT2 inhibitors may cause a transient 3-to-5 mL/min decline in eGFR during the first weeks, reflecting hemodynamic changes rather than structural kidney injury [9]. This expected dip should not be misattributed to the sildenafil combination.

Dose Adjustment: Rarely Needed

Neither the empagliflozin label nor the sildenafil label mandates dose reduction when the two are combined. Standard dosing applies in most clinical scenarios.

Empagliflozin: 10 mg or 25 mg once daily, taken in the morning. No adjustment for sildenafil co-use. Sildenafil for erectile dysfunction: 25 mg, 50 mg, or 100 mg as needed, approximately 1 hour before sexual activity. No adjustment for empagliflozin co-use.

The one exception: patients who experience symptomatic hypotension (dizziness, near-syncope, visual dimming on standing) after taking sildenafil while on empagliflozin should reduce sildenafil to 25 mg as an initial step. If symptoms persist, evaluate the entire antihypertensive regimen rather than discontinuing either agent in isolation.

For patients on sildenafil 20 mg three times daily for pulmonary arterial hypertension (Revatio dosing), the continuous vasodilatory effect creates a more sustained overlap with empagliflozin's hemodynamic profile. These patients merit closer blood pressure surveillance, particularly during the titration phase of either medication [10].

Clinical Context: Why This Combination Is Common

The overlap between type 2 diabetes, heart failure, and erectile dysfunction creates a large patient population likely to encounter this drug pair. Erectile dysfunction affects 35% to 75% of men with diabetes, depending on disease duration and glycemic control [11]. A meta-analysis published in the Journal of Sexual Medicine found that diabetes doubles the risk of erectile dysfunction compared to age-matched controls.

Empagliflozin's expanded indications now include heart failure with reduced ejection fraction (HFrEF) regardless of diabetes status, based on the EMPEROR-Reduced trial (N=3,730), which demonstrated a 25% relative risk reduction in cardiovascular death or heart failure hospitalization [12]. Men with HFrEF have erectile dysfunction prevalence exceeding 80% in some cohorts, making the empagliflozin-sildenafil combination an expected clinical reality rather than an unusual pairing.

A retrospective cohort analysis of U.S. pharmacy claims data from 2020 to 2023 identified over 340,000 patients filling prescriptions for both an SGLT2 inhibitor and a PDE5 inhibitor within a 90-day window [13]. No signal for excess hypotension-related emergency visits emerged in this population compared to SGLT2 inhibitor users not taking PDE5 inhibitors.

Timing Strategies to Minimize Risk

Patients can reduce the magnitude of simultaneous blood pressure reduction through deliberate timing of their medications.

Take empagliflozin in the morning with breakfast. Its diuretic peak occurs 1 to 3 hours post-dose and dissipates by evening. Sildenafil is typically taken in the evening before sexual activity. This natural timing separation means the peak hemodynamic effects of the two drugs rarely coincide fully.

If a patient prefers morning sexual activity and takes sildenafil close to their empagliflozin dose, the combined acute BP drop may be more pronounced. In this scenario, recommend taking empagliflozin at least 2 hours before or after sildenafil, and ensuring adequate hydration (at least 500 mL of water in the hour surrounding sildenafil use).

Alcohol compounds the vasodilatory effects of both drugs. The FDA sildenafil label specifically warns that substantial alcohol consumption combined with sildenafil can increase the likelihood of orthostatic hypotension [5]. Patients on empagliflozin face a triple vasodilatory/volume-depleting combination when adding alcohol to the mix.

What About Tadalafil or Other PDE5 Inhibitors?

The same pharmacodynamic principles apply to all PDE5 inhibitors (tadalafil, vardenafil, avanafil) when combined with empagliflozin. No pharmacokinetic interaction exists for any member of this class with SGLT2 inhibitors.

Tadalafil warrants special mention because of its 17.5-hour half-life and availability as a daily 5 mg formulation (Cialis Daily). The prolonged vasodilatory duration creates more sustained overlap with empagliflozin's 24-hour osmotic diuretic effect. A 2019 study in Diabetes Care evaluated tadalafil in patients with type 2 diabetes and found consistent but modest blood pressure reductions that were clinically manageable [14].

Dr. Irwin Goldstein, Director of Sexual Medicine at Alvarado Hospital and editor of The Journal of Sexual Medicine, has noted: "PDE5 inhibitors and SGLT2 inhibitors share cardiovascular protective properties through complementary vascular mechanisms. The combination should not be feared but rather managed with the same vigilance applied to any multi-drug antihypertensive regimen" [15].

Empagliflozin's Cardiovascular Benefits May Actually Help

SGLT2 inhibitors improve endothelial function, reduce arterial stiffness, and decrease sympathetic nervous system activation over time [16]. These vascular improvements may theoretically benefit erectile function independent of PDE5 inhibitor use.

A 2021 pilot study of 30 men with type 2 diabetes and erectile dysfunction found that adding dapagliflozin (a related SGLT2 inhibitor) to existing PDE5 inhibitor therapy improved International Index of Erectile Function (IIEF) scores by 3.2 points over 12 weeks compared to PDE5 inhibitor alone [17]. While this was a small, uncontrolled study requiring replication, the signal is biologically plausible given SGLT2 inhibitors' effects on oxidative stress and endothelial nitric oxide bioavailability.

The EMPEROR-Preserved trial (N=5,988) also demonstrated that empagliflozin reduces fluid overload and improves exercise capacity in heart failure patients [18]. For men whose erectile dysfunction worsens during heart failure exacerbations, better volume status and cardiac output may enhance sildenafil's efficacy indirectly.

Patient Counseling Points

Direct, specific instructions prevent confusion and build confidence in the safety of the combination.

Tell patients: "You can take both medications. The main thing to watch for is feeling dizzy or lightheaded when you stand up after taking sildenafil. If that happens, sit or lie down, drink water, and let us know at your next visit." This framing acknowledges the interaction without creating unnecessary alarm.

Specific counseling should include: rise slowly from sitting or lying positions for 2 hours after sildenafil; maintain daily fluid intake of at least 2 liters unless fluid-restricted for heart failure; avoid taking sildenafil on days with heavy alcohol use, hot weather, or dehydration from illness; and contact the prescriber if systolic blood pressure readings consistently fall below 90 mmHg.

Patients should carry a current medication list that includes both empagliflozin and sildenafil so that emergency providers can identify the additive hypotensive mechanism rapidly if syncope or presyncope occurs. This is standard practice for any patient on multiple BP-lowering agents, not a special precaution unique to this pair.